By -Aaksha
By -January 31, 2024
Over 10 million people receive a cancer diagnosis each year. Over half of them live in the developing world, where the cancer incidence rate has reached pandemic proportions. Access to cancer care is becoming increasingly unequal between and within countries, despite significant advancements in the field over the past few decades. The majority of new cancer cases and deaths occur in low- and middle-income countries, despite the fact that the total number of cancer patients worldwide is steadily rising.
Remarkably, Africa, Asia, Central America, and South America account for over 60% of global cancer cases, and these same regions also account for over 70% of cancer-related deaths worldwide. By 2030, seventy percent of newly reported cases of cancer are predicted to occur in developing countries. Furthermore, survival rates are rising in prosperous nations and falling in impoverished ones. An individual's chance of survival for a variety of cancers is positively and closely correlated with the income of their country.
Lack of knowledge, early detection, and prevention, as well as the inaccessibility of new and more effective treatments that have been developed in recent decades and made available to many in the first world, are some of the reasons why low- and middle-income countries lag behind wealthy nations in terms of cancer survival rates. It is estimated that over 30% of cancer-related deaths in developing nations could be prevented. Just as neglecting care results in needless death and suffering, neglecting prevention leads to overwhelming and unaffordable treatment demands.
Cancer care and control should be made readily accessible to all people worldwide, with special focus on treating cancers that are curable or preventable and providing palliative care for those that cannot. It is possible to determine strategies that effectively reduce the burden of cancer and broaden health services in developing countries. Creating new infrastructure, training oncologists and paraprofessionals, and taking advantage of technology, particularly telecommunications with oncologists to overcome geographic constraints, can help in minimizing cancer burden. Secondly, creating and executing pricing and procurement guidelines at the regional, international, and group levels to provide opportunities for group bargaining in an effort to bring down the cost of necessary services, medications, and immunisations. Third, increasing the amount of money available for cancer treatment, palliation, and prevention, identifying and applying creative financing methods.
The following article can help you to reach the best facilities in the world that are providing cancer care.
Dr. Theodore Ross, a certified colorectal surgeon, is affiliated with Cleveland Clinic Canada, focusing on gastrointestinal disorders and issues affecting the colon and rectum. With over 28 years of experience, he has served in the Department of Surgery at the University of Toronto and is a member of the active staff at Sunnybrook Health Sciences Center. Dr. Ross boasts a distinguished career encompassing clinical practice, academia, and research.
Dr. Christopher Wolfgang serves as the director of NYU Langone Health's recently established Division of Hepatobiliary & Pancreatic Surgery, renowned for his expertise in pancreatic cancer oncology. With over 1,200 pancreatic procedures performed, he brings extensive experience to the field. The new division aims to deliver exceptional care for malignancies and conditions affecting the bile duct, gallbladder, fatty liver, and pancreas. Previously, Dr. Wolfgang held positions as the Director of Hepatobiliary and Pancreatic Surgery at Johns Hopkins and as a Professor of Surgery. His primary research focus lies in understanding the biological behavior of pancreatic tumors, while his clinical interests encompass cancers and non-cancerous conditions of the liver, pancreas, bile duct, and gallbladder.
Dr. Rachel Dultz, a board-certified surgeon and Fellow of the American College of Surgeons specializing in breast surgical oncology (FACS), brings over 27 years of experience to her practice. Since 1998, she has provided care to individuals with breast-related concerns in Princeton and neighboring regions. Dr. Dultz established her private clinic within the Breast Health Center in East Windsor in January 2009, dedicated exclusively to patients with breast diseases.
Brian P. Marr serves as the Director of Ophthalmic Oncology at New York-Presbyterian/Columbia University Irving Medical Center, boasting over 27 years of experience in ophthalmology with a specialization in eye cancers. He is among the few ophthalmologists nationwide trained comprehensively in all aspects of eye cancer care and possesses extensive clinical expertise in treating various eye conditions associated with cancer. Dr. Marr is globally recognized as one of the foremost Ocular oncologists, with his interest in ophthalmic oncology cultivated during an eight-year tenure with Wills Eye Hospital's Ocular Oncology Service. During this period, he gained proficiency in managing intraocular malignancies as well as tumors affecting the eyelid, orbit, and conjunctiva.
Dr. Omar Khan, a highly seasoned specialist in medical oncology located in Swindon, boasts over two decades of experience in the field. Renowned globally for his expertise in lung cancer treatment, he focuses on addressing a range of cancers such as lung, bladder, prostate, stomach, and kidney cancer, as well as mesothelioma and immunotherapy.Notably, his pioneering research on cancer biomarkers at the University of Oxford culminated in the award of a DPhil in 2013.
Dr. Saifee Mullamitha serves as a senior consultant medical oncologist at the Christie Hospital in Manchester, renowned as one of Europe's premier cancer treatment facilities. His expertise lies in the management of colorectal cancer, encompassing both its early and advanced stages. Dr. Mullamitha offers guidance on diverse aspects of systemic treatment, including the applicability of immunotherapy.
Professor Dr. Anca-Ligia Grosu is an esteemed Radiation Oncologist with more than 25 years of experience in the field. She holds memberships in numerous academic and professional associations, such as the German Neuro-oncology Working Group (NOA), the International Association of Surgeons, Gastroenterologists, and Oncologists (IASGO), among others.
Professor Dr. Dimos Baltas brings over 32 years of experience to the field of radiation oncology. He holds membership in several esteemed organizations, including the German Society for Medical Physics (DGMP), the American Association of Physicists in Medicine (AAPM), the European Society for Radiotherapy and Oncology (ESTRO), the German Society for Radiation Oncology (DEGRO), the Hellenic Association of Medical Physicists (EFIE), and the American Brachytherapy Society (ABS), among others. In 1996, he was appointed as an Adjunct Research Associate University Professor in the Department of Medical Physics and Engineering at the Institute for Communication and Computer Systems (ICCS) at the National Technical University of Athens.
Dr. Suresh H. Advani is a highly esteemed figure in the fields of medical oncology, pediatric oncology, and hematology, boasting over 48 years of experience in cancer treatment. Among his notable achievements, he was the first to successfully conduct a bone marrow transplant. He has received prestigious honors, including the Padma Bhushan Award in 2012 and the Padma Shri Award in 2002, both being the highest civilian honors in India. Additionally, he has been recognized with the Dhanvantari Award (2002), the Dr. B. C. Roy National Award (2005), the Rashtriya Krantiveer Award (2014), and the Harvard Medical International's Lifetime Achievement in Oncology (2005).
Dr Rajasundaram S brings over 25 years of experience as a Surgical Oncologist in South India. He is internationally recognized as one of the leading experts in ovarian oncology. Currently, he holds the position of Director of Oncology at Gleneagles Global Health City in Chennai. Throughout his career, he has successfully completed more than 18,000 major procedures, including complex head and neck surgeries involving microvascular reconstruction. His expertise lies in laparoscopic gastrointestinal and gynecological oncology surgeries, as well as advanced breast cancer surgeries such as onco-plastic reconstruction and sentinel lymph node biopsy. He is actively involved in delivering guest lectures both nationally and internationally. For the past two decades, he has served as a senior consultant in various academic institutions. Additionally, he remains an active member of esteemed oncology organizations, including IASO, ISO, AROI, ESMO, OGGSI, among others.
Dr. Hassan Ghazal is a prominent medical oncologist and hematologist based in Dubai, boasting over 25 years of experience in the field. His expertise spans areas such as bone marrow transplantation, blood disorders, and hemato-oncology. He holds membership in esteemed medical societies, including the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, and the European Society of Medical Oncology.
How long does cancer treatment typically last in India?
A course consists of several treatment cycles. A course of treatment typically lasts three to six months, though it can last longer. During that time, you would likely have four to eight treatment cycles.
What types of cancer do the best oncologists specialize in treating?
Leukaemia, lymphoma, and myeloma are among the blood cancers that hematologist-oncologists treat. Cancers of the nervous system, spine, and brain are treated by neuro-oncologists. Cancer in children and teenagers is treated by pediatric oncologists.
Subscribe to our Newsletter and make your informed health decisions. Get essential health insights and updates delivered straight to your inbox. Join now for a healthier you.
